CJC-1295/DAC

Description

DESCRIPTION

CJC-1295 with DAC (Drug Affinity Complex) is a long‑acting, tetrasubstituted GHRH analog designed to extend growth hormone (GH) and IGF‑1 elevation through prolonged half‑life and peptide stabilization. The DAC modification enables binding to serum albumin, supporting sustained endocrine signaling, GH pulsatility modeling, and metabolic‑pathway investigations. Research applications frequently include cellular repair, endocrine regulation, and mitochondrial performance studies under controlled laboratory conditions.

LYOPHILIZED PEPTIDES

This peptide is freeze‑dried to preserve purity, structural integrity, and molecular stability. No fillers or excipients are used in the lyophilization process.

RESEARCH APPLICATIONS

1 — Sustained GH Release & Endocrine Regulation

CJC‑1295 DAC is widely studied for its long‑acting ability to elevate GH and IGF‑1 through extended GHRH‑receptor stimulation. Research models examine GH pulsatility, endocrine feedback loops, and long‑interval receptor activation patterns relevant to hormonal regulation.

(References: Nature—https://www.nature.com/articles/ijo2013172, PubMed—https://pubmed.ncbi.nlm.nih.gov/17132220/ )

2 — Cellular Repair & Protein Synthesis Pathways

Extended GH/IGF‑1 elevations produced by CJC‑1295 DAC are investigated for influences on cellular recovery, anabolic signaling, and mitochondrial function. Studies evaluate its effects on protein synthesis, tissue‑repair cascades, and metabolic resilience in vitro and in vivo.

(References: ScienceDirect—https://www.sciencedirect.com/science/article/pii/S0026049522001033, PubMed—https://pubmed.ncbi.nlm.nih.gov/18031563/ )

3 — Metabolic & Mitochondrial Activity Modeling

Research explores how long‑acting GHRH analogs influence lipid metabolism, glucose utilization, mitochondrial biogenesis, and metabolic balance under stress. CJC‑1295 DAC is used in metabolic‑optimization and biochemical‑adaptation studies.

(References: Frontiers—https://www.frontiersin.org/articles/10.3389/fendo.2021.791797/full, PubMed—https://pubmed.ncbi.nlm.nih.gov/16705063/ )

SPECIFICATIONS

Property | Details

Peptide Name | CJC‑1295 with DAC (Drug Affinity Complex)

Amino Acid Sequence | Modified GHRH1‑29 sequence + Drug Affinity Complex

Molecular Formula | C165H269N47O46

Molecular Weight | ~3367.87 g/mol

CAS Number | 863288‑34‑0

Purity | ≥ 99% (HPLC verified)

Appearance | White to off‑white lyophilized powder

Solubility | Soluble in bacteriostatic water

Storage | Store dry at 2–8 °C; after reconstitution refrigerate ≤ 30 days

Usage | Laboratory research only

Research Data & References

– GH secretion dynamics: https://pubmed.ncbi.nlm.nih.gov/17132220/

– Endocrine feedback studies: https://pubmed.ncbi.nlm.nih.gov/16522641/

– Cellular repair pathways: https://pubmed.ncbi.nlm.nih.gov/18031563/

– Metabolic signaling & IGF‑1 modulation: https://pubmed.ncbi.nlm.nih.gov/16705063/

Disclaimer — Research Use Only

All information presented herein is intended solely for laboratory and educational research. These materials are not approved for human or veterinary use, nor for diagnostic or therapeutic application. Descriptions of biochemical activity are provided for informational context only and must not be interpreted as medical advice. Researchers are expected to handle all compounds in compliance with local regulations and institutional safety standards. EOC Labs supports responsible, ethical, and compliant scientific inquiry.